

HORMONE RECEPTOR-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED NO PRIOR ENDOCRINE THERAPY 8-2-2016

OVERVIEW

1. Background

There is a lack of epidemiological data on the incidence and prevalence of endocrine treatment-naive hormone receptor (HR)-positive locally advanced/metastatic breast cancer (LA/MBC). We analysed data from European cancer registries to assess the epidemiology of postmenopausal women with endocrine therapy-naive HR positive LA/MBC.

2. Goal

We analysed data from European cancer registries to assess the epidemiology of postmenopausal women with endocrine therapy-naive HR positive LA/MBC.

3. Methodology

international, observational retrospective study, conducted by the European Registry of Cancer Care (EURECCA)

4. Study population

Endocrine treatment-naive hormone receptor (HR)-positive locally advanced/metastatic breast cancer (LA/MBC)

5. Countries

Belgium, England, Germany, Ireland, Norway and The Netherlands

6. Progress

Abstract send to EBCC
Number of patients: 218,585 postmenopausal women

WORK GROUP

Name	
Tom Børge Johannesen	Norway
Riccardo Audisio	UK
Simone Schrodi	Germany
Esther Bastiaannet	Netherlands
Sabine Siesling	Netherlands
Petra Boelens	Netherlands
Cornelis van de Velde	Netherlands
Liesbet van Eycken	Belgium
Paul Walsh	Ireland